

Supplementary Table 15: Goodness of fit statistics for IPW comparison of CD patients from start 1L to censoring

Characteristic	Difference (ADA – IFX) ¹	95% CI ¹	Difference (UST – IFX) ¹	95% CI ¹	Difference (VDZ – IFX) ¹	95% CI ¹
Patient Sex	0.00	–0.11, 0.11	0.04	–0.08, 0.15	0.05	–0.06, 0.16
Patient Age	0.00	–0.11, 0.11	0.02	–0.09, 0.13	0.02	–0.09, 0.13
CCI	0.00	–0.11, 0.11	–0.01	–0.12, 0.10	–0.03	–0.14, 0.09
Number of corticosteroid prescriptions	0.00	–0.11, 0.11	0.05	–0.06, 0.16	0.06	–0.05, 0.17
Number of hospitalizations	0.00	–0.11, 0.11	0.06	–0.05, 0.18	0.01	–0.10, 0.12
Number of comorbidities	0.00	–0.11, 0.11	0.11	0.00, 0.22	0.07	–0.05, 0.18
Number of injuries in follow-up	0.04	–0.07, 0.15	0.08	–0.03, 0.19	–0.02	–0.13, 0.10

ADA = Adalimumab CCI = Charlson Comorbidity Index CD = Crohn’s disease CI = Confidence Interval IFX = Infliximab IPW = inverse probability weighting UST = Ustekinumab VDZ = Vedolizumab

¹Standardized Mean Difference